TACSTD2 and neoplasm: Strikingly, the abnormal localization of CLDN1 and OCLN that we documented following TACSTD2 silencing both in hepatoma cell lines and in primary human hepatocytes was analogous to that observed in tumor tissue of patients with HCV-associated HCC (Fig 1E).